Results

Total Results: 2,078 records

Showing results for "drugs".

61. Addressing Knowledge Gaps in the Treatment of Hypertension Using ACE/ARB Therapies | Effective Health Care (EHC) Program
    effectivehealthcare.ahrq.gov/products/hypertension-treatment-knowledge-gaps/abstract
    January 01, 2005 - Commonly used two classes of drugs, angiotensin converting enzyme inhibitors (ACEIs) and angiotensin … actionable information for patients, physicians and policy makers to make decision in uses of these drugs

62. Evaluation of Effectiveness and Safety of Antiepileptic Medications in Patients With Epilepsy (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/epilepsy-medicine_research-protocol.pdf
    February 01, 2008 - Antiepileptic Drugs. Fifth ed. … Antiepileptic Drugs. Fourth ed. New York, Raven Press; 1995. p. 799-806. 19. … Antiepileptic Drugs. Fifth ed. … Therapeutic equivalence of generic drugs letter to health practitioners. … Are there potential problems with generic substitution of antiepileptic drugs?

63. Efficacy and Comparative Effectiveness of Off-Label Use of Atypical Antipsychotics – Update | Effective Health Care (EHC) Program
    effectivehealthcare.ahrq.gov/products/atypical-antipsychotics-off-label-update/research-protocol
    May 19, 2010 - These drugs have been studied for off-label use in several conditions. … 84 published studies on atypical antipsychotics and found that the most common off-label uses of the drugs … Sub-Question 2: How do atypical antipsychotic medications compare with other drugs, including first … How do they compare within the class and with other drugs used for the conditions? … across condition, and then compared within the class and with other drugs used for the conditions.

64. S9 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/s9.pdf
    October 01, 2007 - detailed (including beneficiary identifiers, contract identifiers pharmacy provider infor- mation on drugs … Key Words: Medicare, Part D, pharmaceuticals (Med Care 2007;45: S9–S12) The Medicare Part D benefit … Part D plan covers 15%, and the beneficiary pays a 5% coinsurance, or copayments of $2 for generic drugs … and $5 for nongeneric drugs. … Drugs provided (including the National Drug Classifica- tion �NDC� code, compound code, and quantity

65. Nonopioid Pharmacologic Treatments for Chronic Pain: Evidence Summary (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/nonopioid-chronic-pain-summary.pdf
    April 01, 2020 - for Chronic Pain: Evidence Summary Purpose of Review Evaluate the benefits and harms of nonopioid drugs … neuropathy/post-herpetic neuralgia and fibromyalgia, and small with nonsteroidal anti-inflammatory drugs … (NSAIDs), acetaminophen, topical formulations such as capsaicin, and drugs used for other conditions … Few differences were found between drugs. … Differences were not found between drugs or doses.

66. PULMONARY with "Discussions" in Exec Summary (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pulmonary-horizon-scan-high-impact-1506.pdf
    October 01, 2015 - Boston (MA): Vertex Pharmaceuticals, Inc.; 2014 Nov 05 [accessed 2014 Dec 11]. [3 p]. … Boston (MA): Vertex Pharmaceuticals Inc.; 2015 Jan 11 [accessed 2015 May 13]. [5 p]. … Boston (MA): Vertex Pharmaceuticals Inc.; 2015 May 12 [accessed 2015 May 13]. [2 p]. … Boehringer Ingelheim Pharmaceuticals, Inc. … Ridgefield (CT): Boehringer Ingelheim Pharmaceuticals, Inc.; 2014 Oct. 18 p.

67. #14 SUBSTANCE ABUSE (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/14_substanceabuse_potential_high_impact_june_2012.pdf
    January 01, 2012 - Coordinating Council for Comparative Effectiveness Research, AHRQ is interested in innovations in drugs … For purposes of horizon scanning, AHRQ’s interests are broad and encompass drugs, devices, procedures … Information is compiled for expert comment on topics at a granular level (i.e., similar drugs in the … However, experts shared the belief that these drugs’ benefits would prove to be only incremental … Prescription drugs: abuse and addiction. [internet].

68. #05 DEPRESSION (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/depression-horizon-scan-high-impact-1506.pdf
    June 01, 2015 - health care sector, horizon scanning pertains to identification of new (and new uses of existing) pharmaceuticals … Available: http://www.cesar.umd.edu/cesar/drugs/ketamine. pdf. 4. … CNS Drugs. 2012 Mar 1;26(3):189-204. … http://www.cesar.umd.edu/cesar/drugs/ketamine.pdf http://www.cesar.umd.edu/cesar/drugs/ketamine.pdf http … Rochester (MI): JHP Pharmaceuticals, LLC; 2011 Jun. 4 p.

69. #06 Developmental Delays ADHD, and Autism (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/06_devdelays_potential_high_impact_2012-12-10.pdf
    January 01, 2012 - Coordinating Council for Comparative Effectiveness Research, AHRQ is interested in innovations in drugs … In the health care sector, horizon scanning pertains to identifying new (and new uses of existing) pharmaceuticals … For purposes of horizon scanning, AHRQ’s interests are broad and encompass drugs, devices, procedures … Information is compiled for expert comment on topics at a granular level (i.e., similar drugs in the … These drugs will probably face intense scrutiny, considering the challenges of accurately diagnosing

70. Topic Suggestion Description | Effective Health Care Program
    effectivehealthcare.ahrq.gov/get-involved/nominated-topics/the-american-college-of-chest-physicians-accp-proposes-to-update-the-medical-therapies-section-of-2007-updated-publication-on-medical-therapies-for-pulmonary-arterial-hypertension-accp-evidence-based-clinical-practice-guideli
    January 01, 2007 - yes If yes, explain the specific technologies, devices, drugs, or interventions you would like to … see compared: 2 new drugs have now been approved for the treatment of PAH: inhaled treprostinil … ambrisentan Comparisons should be made between these new drugs and the older ones, listed here by … Side effects of various drugs include but are not limited to liver function abnormalities, elevated serum … Since the 2007 update of the medical therapies section of the 2004 guidelines, 2 new drugs have been

71. Layout 1 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/rheumatoid-arthritis-2007_executive.pdf
    January 01, 2007 - Available therapies for RA include corticosteroids; synthetic disease-modifying antirheumatic drugs, … Finally, very little is known about the benefits or risks of these drugs in different patient subgroups … : comparative risk of harms: infliximab) vs. anti-TNF Moderate Low drugs Biologic DMARDs vs. … Moderate Moderate In patients with no previous use of study drugs, higher ACR 20/50 response rates … Adjusted indirect comparisons also indicated that anakinra has lower efficacy than anti-TNF drugs.

72. Dietary-Supplements Executive (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/dietary-supplements_executive.pdf
    April 01, 2012 - Comparative Effectiveness Review Number 51 Dietary Supplements in Adults Taking Cardiovascular Drugs … (when compared with cardiovascular drugs alone or cardiovascular drugs and a different dietary supplement … • Studies included cardiovascular drugs not marketed in the United States. … Drugs Aging. 2009 Dec;26(Suppl 1):41-51. PMID: 20136168. 13. Garner JB. … Dietary Supplements in Adults Taking Cardiovascular Drugs.

73. DEcIDE 32: The Incident User Design in Comparative Effectiveness Research (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/incident-user-design_research.pdf
    May 01, 2012 - ...............................................................................3 Recently Marketed Drugs … If newer drugs were started more recently, the newer drugs may appear safer than older drugs because … their apparent rate would be lower; investigators would observe a higher event rate for older drugs … in a class; requiring all patients in the cohort to have a 365-day window without use of any drugs … For drugs that are available as combination products, it is important to handle the baseline period

74. Layout 1 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/juvenile-arthritis-dmards_executive.pdf
    September 01, 2011 - Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA) … Treatment with the class of agents known as disease-modifying anti- rheumatic drugs (DMARDs) has become … , which are created by biologic processes, or non-biologic drugs, which are manufactured chemically. … Furthermore, it is possible that the effectiveness of these drugs varies by category of JIA. … be used for difficult-to-treat JIA, or the impact of using multiple drugs.

75. The Incident User Design in Comparative Effectiveness Research | Effective Health Care (EHC) Program
    effectivehealthcare.ahrq.gov/products/incident-user-design/research
    May 15, 2012 - coronary heart disease events among patients using COX-2 selective non-steroidal anti-inflammatory drugs … For older drugs, a 365-day window may identify patients starting a new episode of therapy, but not … Most of these patients used other disease-modifying antirheumatic drugs (DMARDs) and have now switched … If newer drugs were started more recently, the newer drugs may appear safer than older drugs because … COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease.

76. Evidence-based Practice Center Systematic Review Protocol (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/migraine-prevention_research-protocol.pdf
    November 03, 2011 - The FDA has approved no drugs for migraine prevention in children. … prevention, which include novel antiepileptic drugs, calcium channel modulators, glutamate blockers … o Use of drugs for acute migraine (prescribed or over-counter). … Drugs approved by the FDA for migraine prevention and off-label drugs examined in clinical trials. … Studies that examined eligible drugs on populations with other diseases.

77. S29 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/s29.pdf
    October 01, 2007 - it involved 2 short-term drugs instead of 2 long-term drugs? … Changes could also confuse physicians; confusion could generalize beyond the study drugs. … Some leaders noted that newer drugs are not typically included on their formulary. … Including short term drugs would be more challenging. … Make clear that physicians have flexibility to prescribe nonstudy drugs.

78. Cover Page (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/it-architecture-for-post-marketing-surveillance-arizona-cert.pdf
    September 01, 2007 - For example, although 15 drugs were withdrawn from the market between 1997 and 2005 based on MedWatch … The surveillance administration process involves the identification of newly introduced drugs that … No effective mechanism currently exists for tracking the purchase of such drugs. … Such dispensation of drugs by the physicians may need to be monitored, especially for drugs that have … In order to cater to this need, all drugs taken by patients will need to be monitored.

79. Cover Page (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/medicine-safety-call-center_research.pdf
    September 01, 2007 - For example, although 15 drugs were withdrawn from the market between 1997 and 2005 based on MedWatch … The surveillance administration process involves the identification of newly introduced drugs that … No effective mechanism currently exists for tracking the purchase of such drugs. … Such dispensation of drugs by the physicians may need to be monitored, especially for drugs that have … In order to cater to this need, all drugs taken by patients will need to be monitored.

80. Immune System and Disorders | Effective Health Care (EHC) Program
    effectivehealthcare.ahrq.gov/health-topics/immune-system-and-disorders
    July 16, 2013 - Protocol October 11, 2016 The Effectiveness of Disease-Modifying Antirheumatic Drugs … – An Update Research Protocol May 24, 2017 Disease-Modifying Antirheumatic Drugs